Voltage-Gated Potassium Channel Opener Bioavailability Through Fed Dosing
Solution Overview
Problem
Current antiepileptic drugs (AEDs) have minimal effect on neuronal potassium-gated channels, leaving up to 30% of patients with epilepsy refractory to conventional treatment, and there is a need for improved methods to enhance the bioavailability and exposure of potassium channel openers like Compound A when orally administered.
Innovation Solution
Oral administration of Compound A under fed conditions, defined as having food within a specific time frame before and after dosing, significantly enhances its bioavailability and exposure compared to fasted conditions, increasing parameters such as Cmax, AUCinf, Tmax, and t1/2λz.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If Compound A is orally administered under fasted conditions, then the administration is simple and convenient, but the bioavailability and exposure are insufficient
Solution Approach 1:
The patent changes the environmental parameter of food intake timing to optimize drug absorption. By specifying that Compound A should be administered under fasted conditions (no food for at least 4 hours before and 2 hours after dosing), the patent achieves improved bioavailability and exposure parameters (AUC, Cmax, Tmax) without requiring formulation modifications.
2Reliability
If the dosage of Compound A is increased to achieve therapeutic effect, then the therapeutic efficacy improves, but the risk of adverse effects increases
Solution Approach 1:
The patent changes the absorption parameter through fasting conditions, which increases bioavailability. This allows lower dosages to achieve the same therapeutic effect, thereby reducing the risk of concentration-dependent adverse effects while maintaining therapeutic efficacy.
3Duration of action of moving object
If multiple dosing administrations are given to maintain therapeutic levels, then the therapeutic coverage is improved, but the accumulation of drug and potential toxicity increases
Solution Approach 1:
The patent modifies the absorption parameter by requiring fasted conditions, which extends the elimination half-life (t1/2λz) and area under the curve (AUC). This enhanced exposure profile allows for less frequent dosing intervals while maintaining therapeutic levels, thereby reducing the risk of accumulation and toxicity.
Data Source
AI summary
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.